Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Accumulated Expenses (2020 - 2025)

Barinthus Biotherapeutics' Accumulated Expenses history spans 6 years, with the latest figure at $6.2 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 34.39% year-over-year to $6.2 million; the TTM value through Dec 2025 reached $6.2 million, down 34.39%, while the annual FY2025 figure was $6.2 million, 34.39% down from the prior year.
  • Accumulated Expenses reached $6.2 million in Q4 2025 per BRNS's latest filing, down from $6.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $10.3 million in Q2 2024 to a low of $9000.0 in Q2 2022.
  • Average Accumulated Expenses over 5 years is $5.0 million, with a median of $6.8 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: plummeted 92.24% in 2022, then skyrocketed 35341.38% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $7.9 million in 2021, then rose by 2.36% to $8.1 million in 2022, then increased by 14.28% to $9.2 million in 2023, then grew by 3.4% to $9.5 million in 2024, then tumbled by 34.39% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Accumulated Expenses are $6.2 million (Q4 2025), $6.7 million (Q3 2025), and $7.4 million (Q2 2025).